Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
You may also be interested in...
The Booming Business Of Drug Exclusions
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing
Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.
Novartis Q2 Preview: Where Is The Next Blockbuster Coming From?
Entresto and Cosentyx continue to grow but investors will be looking to see if there are candidates in the current portfolio or pipeline that could join them in the mega-blockbuster club.